Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | DHODH | Q02127 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3187232 | 1.00 | MAPT (0.58) | MAPTLMNAGLO1KMT2AMEN1 | |
| SCHEMBL3187242 | 1.00 | MAPT (0.58) | MAPTLMNAGLO1KMT2AMEN1 | |
| SCHEMBL3569867 | 0.85 | ALDH1A1 (0.48) | MAPTLMNAGLO1KMT2AMEN1 | |
| SCHEMBL3569865 | 0.85 | ALDH1A1 (0.48) | MAPTLMNAGLO1KMT2AMEN1 | |
| SCHEMBL14853125 | 0.81 | MAPT (0.45) | MAPTLMNAGLO1KMT2AMEN1 | |
| SCHEMBL17491137 | 0.81 | MAPT (0.45) | MAPTLMNAGLO1KMT2AMEN1 | |
| SCHEMBL31238871 | 0.81 | MAPT (0.45) | MAPTLMNAGLO1KMT2AMEN1 | |
| SCHEMBL275027 | 0.81 | MAPT (0.47) | MAPTLMNAGLO1KMT2AMEN1 | |
| SCHEMBL742994 | 0.81 | MAPT (0.47) | MAPTLMNAGLO1KMT2AMEN1 | |
| SCHEMBL742993 | 0.81 | MAPT (0.47) | MAPTLMNAGLO1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7671069-B2 | Tricyclic, heteroaromatic compounds modulating CXCR4 and/ or CXCR7 | CHEMOCENTRYX, INC. (US) | 2010-03-02 | — | — | US | disclosed |
| US-20070254915-A1 | CXCR4 MODULATORS | CHEMOCENTRYX, INC. (US) | 2007-11-01 | — | — | US | disclosed |
| WO-2007115232-A2 | CXCR4 MODULATORS | CHEMOCENTRYX, INC. (US) | 2007-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254915-A1 | CXCR4 MODULATORS | CXCL12, CXCR4, CXCR1 | MAPT 2809/4885LMNA 4638/4885GLO1 4854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.